Related Experiment Video
Updated: Sep 20, 2025

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Impact of Polygenic Interactions With Anticholinergic Burden on Cognition and Brain Structure in Psychosis Spectrum
Lusi Zhang1, Elena I Ivleva1, David A Parker1
1Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis (Zhang, Bishop); Department of Psychiatry, Southwestern Medical Center, University of Texas, Dallas (Ivleva, Tamminga); Department of Psychology and Neuroscience, University of Georgia, Athens (Parker, McDowell, Clementz); Department of Human Genetics, Emory University School of Medicine, Atlanta (Parker); Department of Psychology, Rosalind Franklin University of Medicine and Science, North Chicago (Hill); Department of Psychiatry (Lizano, Keshavan) and Division of Translational Neuroscience (Lizano), Beth Israel Deaconess Medical Center, Boston; Department of Psychiatry, Harvard Medical School, Boston (Lizano, Keshavan); Departments of Psychiatry, Neuroscience, and Psychology, Duke University, Durham, NC (Keefe); Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago (Keedy, Gershon); Departments of Psychiatry and Neurobiology, School of Medicine, Yale University, New Haven, CT (Pearlson); Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati (Sweeney); Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School, Minneapolis (Bishop).
Objective:
The authors sought to determine whether genetic predispositions to cognitive ability or psychiatric conditions interact with anticholinergic burden (AChB) to impact cognition and brain structure in individuals with psychotic disorders.
Methods:
Participants with psychosis spectrum disorders (N=1,704) from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP) consortium, 18-65 years of age and representing diverse ancestries, underwent cognitive assessments, structural neuroimaging, genotyping, and a comprehensive medication review. The primary cognitive outcome was the Brief Assessment of Cognition in Schizophrenia (BACS) composite score, and the primary brain structural phenotype was total gray matter volume. AChB scores for scheduled medications were quantified using the CRIDECO Anticholinergic Load Scale. Polygenic scores (PGSs) for cognition, schizophrenia, bipolar disorder, and depression were constructed, and a composite psychiatric PGS was subsequently generated. Linear regression models were used to examine AChB-PGS interactions and their associations with cognitive and brain structure outcomes, adjusting for clinical covariates and multiple testing with false discovery rate. Hypothesis-driven moderated mediation models were used to explore potential association pathways.
Results:
Higher AChB was significantly associated with lower BACS performance and reduced gray matter volume. Individuals with higher cognitive PGS values exhibited greater adverse effects of AChB on BACS, while those with lower composite psychiatric PGS values showed more pronounced gray matter volume reductions from AChB. AChB associations with cognitive impairment were partially mediated by reduced gray matter volume and were moderated by composite psychiatric PGS.
Conclusions:
Anticholinergic-polygenic interactions significantly impact cognition and brain structure in individuals with psychotic disorders, highlighting a novel gene-by-environment interaction that advances our mechanistic understanding of cognitive impairments in this population.
More Related Videos
07:30Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
Published on: August 18, 2020
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Related Concept Videos
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Psychosis and Antipsychotic Drugs: Overview
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Psychosis: Goals of Pharmacotherapy
Psychological and Sociocultural Causes of Schizophrenia
Drug Therapy
Antianxiety Medications